Ingredion Incorporated heads into its July 28 earnings report with short interest climbing sharply and the Street increasingly cautious — a combination that sharpens the stakes around what the quarter actually delivers.
The most striking move this week is in short positioning. Short interest jumped 26.5% over the past seven days to 5.5% of the free float — roughly 3.5 million shares — its highest level in the 30-day window. The intraday swings have been dramatic: shares short hit 4.5 million on July 1 before retreating 23.6% the following session, suggesting active repositioning rather than a steady directional bet. Despite the volatility, the month-on-month trend is clearly upward, with SI now 7% above its May baseline. The borrowing market, however, stays wide open. Availability is running near 990% — almost ten times the volume of shares already borrowed sits unused in the lending pool — and cost to borrow is just 0.48%, barely changed from a month ago. That combination tells the same story: shorts are building, but there is no squeeze pressure, no scarcity of borrow, and no urgency in the lending market. Options traders paint a calmer picture. The put/call ratio is 0.41, fractionally below its 20-day average of 0.43 and close to the bottom half of its 52-week range. If options positioning is any guide, the demand for downside protection is actually slipping, even as short sellers add exposure — a meaningful divergence worth watching.
The analyst community has turned more guarded in recent months. Oppenheimer downgraded INGR to Perform from Outperform in early June, having already trimmed its target in April. Before that, Barclays cut its target from $128 to $120 after Q1 results in May while keeping an Equal-Weight rating, and UBS shaved its Neutral target from $124 to $122 in April. The result is a consensus hold rating with a mean price target near $122 — roughly 25% above Thursday's close of $97.62. That gap is notable, but the direction of travel on targets has been consistently downward since February, when Barclays and UBS were both lifting numbers. Benchmark initiated with a Buy and a $130 target in March, adding one lone bull voice. On valuation, the stock trades at a PE of 8.75x and EV/EBITDA of 5.75x, both drifting lower over the past 30 days. The earnings yield has improved to about 11.4%, and ORTEX factor scores put the dividend rank at a solid 73rd percentile — offering income support, though the most recent dividend data in the snapshot predates recent quarters, so yield calculations should be treated with some caution.
First Trust Advisors added over a million shares in the latest reported period, lifting its stake to 4.84% of shares outstanding — the biggest absolute change among the top 15 holders. BlackRock also added around 228,000 shares, now holding just over 10% of the company. Against that institutional accumulation, insider flows remain a mild headwind. CEO James Zallie sold approximately $1.16 million of stock in February at $116.55, alongside CFO James Gray and the Chief Commercial Officer. All trades cleared well above the current price of $97.62. These were likely scheduled sales given the relatively low trade-significance scores, but the directional signal is the same: senior management was a net seller into strength that the stock has since given up.
The stock has lost 4% over the past month, though it recovered nearly 1% this week to $97.62. That compares to a stronger week for several agricultural peers: FLO rallied 13.6%, GIS gained 6.1%, and JBSS added 6.7%, suggesting Ingredion has underperformed its peer basket meaningfully in the past five sessions. The ORTEX short score eased to 44.1 on July 2 from a mid-week peak of 52.3, a directional improvement but still mid-range and consistent with the rebuilding short interest story. Momentum remains the weakest pillar in the overall factor picture, with the stock sitting well below its moving average crossover level.
With Q2 results due July 28, the conversation will almost certainly centre on whether commodity input costs and the tariff environment have started to compress margins — the same concern that drove target cuts across the Street over the past three months — rather than on the volume or revenue line alone.
See the live data behind this article on ORTEX.
Open INGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
